Vai al contenuto principale
xMedica

NCT07321899ClinicalTrials.gov

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Transcatheter Tricuspid Valve Replacement Using the Medtronic Intrepid™ TTVR System in Patients With Severe Symptomatic Tricuspid Regurgitation - PATHFINDER

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Interventistico1186 partecipanti ricercati20 centri1 paese

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-07; recorded start 2026-09-11
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 19 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Cardiovascular)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 4 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,186 participants (target), run at 20 sites.

How this score is built
  • Enrolment31/40

    1,186 participants (target)

  • Site count7/25

    4 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 179 months

  • Sponsor scale4/10

    Medtronic Cardiovascular has led 19 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Prospective, global, pre-market, interventional, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation.

Patologie

  • Severe Tricuspid Regurgitation

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Age ≥18 years at the time of consent. * Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT). * Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR. Exclusion Criteria: * Any tricuspid device currently in place. * Anatomic contraindications. * Need for emergent or urgent surgery. * Left ventricular ejection fraction \<25%.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseNon applicabile
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoSINGLE (1)
Arruolamento1186 partecipanti ricercati

Sponsor e collaboratori

  • Medtronic Cardiovascular Sponsor

Bracci e interventi

  • Medtronic Intrepid™ TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation.

  • Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE TTVR in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with Medtronic Intrepid™ TTVR System in patients with severe or greater tricuspid regurgitation who are not eligible for randomization.

Interventi

  • Dispositivo Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

  • Dispositivo Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System

    Transcatheter Tricuspid Valve Replacement

Esiti misurati

  1. Esito primario

    Rate of Major Adverse Events (MAE)

    Orizzonte temporale 30-days post-procedure

  2. Esito primario

    Composite Endpoint: All-cause mortality, Heart failure hospitalization, and tricuspid valve reintervention

    Orizzonte temporale 1-year post-procedure

  3. Esito secondario

    Tricuspid regurgitation (TR) grade reduction

    Total number of patients with at least one grade TR reduction

    Orizzonte temporale 6 months post-procedure

  4. Esito secondario

    Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline

    KCCQ overall summary score is a patient-reported measure of health status. Scores range from 0 to 100 where higher scores reflect better quality of life

    Orizzonte temporale 6 months post-procedure

  5. Esito secondario

    All-cause mortality

    Orizzonte temporale 12 months post-procedure

  6. Esito secondario

    Heart failure hospitalization

    Orizzonte temporale 12 months post-procedure

  7. Esito secondario

    New onset conduction disturbance (NOCD)

    Orizzonte temporale 30 days post-procedure

  8. Esito secondario

    Total procedure time

    Orizzonte temporale Procedure

  9. Esito secondario

    Right ventricle (RV) dysfunction

    Orizzonte temporale 12 months post-procedure

Date

Date
Data di inizio11 settembre 2026 (effettiva)
Conclusione primaria1 settembre 2031 (stimata)
Conclusione1 aprile 2041 (stimata)
Prima pubblicazione7 gennaio 2026 (effettiva)
Ultimo aggiornamento12 novembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltanovembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

20 centri stanno reclutando

United States

United States
StrutturaCittàStato o regioneStato
Emory University Hospital MidtownAtlantaGeorgiaIn reclutamento
University of Alabama at Birmingham (UAB) HospitalBirminghamAlabamaIn reclutamento
Buffalo General Medical CenterBuffaloNew YorkIn reclutamento
Northwestern Memorial HospitalChicagoIllinoisIn reclutamento
The Christ HospitalCincinnatiOhioIn reclutamento
Cleveland Clinic FoundationClevelandOhioIn reclutamento
Hartford HospitalHartfordConnecticutIn reclutamento
Cedars Sinai Medical CenterLos AngelesCaliforniaIn reclutamento
Northwell Health North Shore University HospitalManhassetNew YorkIn reclutamento
Abbott Northwestern HospitalMinneapolisMinnesotaIn reclutamento
Morristown Medical CenterMorristownNew JerseyIn reclutamento
Yale New Haven HospitalNew HavenConnecticutIn reclutamento
Montefiore Medical CenterNew YorkNew YorkIn reclutamento
NYU Langone Medical CenterNew YorkNew YorkIn reclutamento
The Valley HospitalParamusNew JerseyIn reclutamento
Abrazo Arizona Heart HospitalPhoenixArizonaIn reclutamento
Kaiser Permanente San Francisco Medical CenterSan FranciscoCaliforniaIn reclutamento
Los Robles Hospital & Medical CenterThousand OaksCaliforniaIn reclutamento
Ascension Via Christi Saint FrancisWichitaKansasIn reclutamento
Lankenau Institute for Medical ResearchWynnewoodPennsylvaniaIn reclutamento

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 12 novembre 2026

    Centro aggiunto

    7 sites added (20 total)

    1320

  2. 25 settembre 2026

    Centro aggiunto

    9 sites added (13 total)

    413

  3. 28 luglio 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 28 luglio 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 28 luglio 2026

    Centro aggiunto

    4 sites added (4 total)

    04